Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | ADK | P55263 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CIT | O14578 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12089777 | 0.83 | APP (0.38) | APPKCNH2KDM1AMAP3K11TDO2 | |
| SCHEMBL24784713 | 0.80 | APP (0.36) | APPKCNH2KDM1AMAP3K11TDO2 | |
| SCHEMBL3382791 | 0.78 | KDM1A (0.40) | KCNH2KDM1AADKGAA | |
| SCHEMBL11989533 | 0.77 | APP (0.34) | APPKCNH2KDM1AMAP3K11TDO2 | |
| SCHEMBL14239256 | 0.77 | KCNH2 (0.37) | APPKCNH2GAA | |
| Hydrochloric Acid SCHEMBL9670828 | 0.77 | KCNH2 (0.35) | APPKCNH2KDM1AMAP3K11ADK | |
| SCHEMBL27296333 | 0.77 | KDM4C (0.36) | ADRB2APPTDO2 | |
| SCHEMBL27512329 | 0.76 | PSEN1 (0.38) | APPKCNH2MAP3K11TDO2 | |
| SCHEMBL27512330 | 0.76 | KCNH2 (0.36) | APPKCNH2KDM1AMAP3K11TDO2 | |
| Hydrochloric Acid SCHEMBL31473368 | 0.76 | KDM4C (0.36) | ADRB2APPTDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038264-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-10-26 | — | — | EP | claimed |
| WO-2020035065-A1 | PYRAZOLE DERIVATIVE AS RET INHIBITOR | 南京明德新药研发有限公司 | 2020-02-20 | — | — | WO | disclosed |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2038264-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | GENENTECH, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8846945-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | DILLON MICHAEL PATRICK (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2592070-A2 | Tetrazole-substituted arylamides | F. Hoffmann-La Roche AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20120214789-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | DILLON MICHAEL PATRICK (US) | 2012-08-23 | — | — | US | disclosed |
| US-8193368-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
| US-7595405-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| US-20070203134-A1 | Benzimidazole Acetonitriles | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | P2RX2, P2RX3, TPX2 | ADRB2 489/4885APP 2790/4885KCNH2 1361/4885 |
| US-20070203134-A1 | Benzimidazole Acetonitriles | PKD1, GPR119, CCNI | ADRB2 2271/4885APP 3234/4885KCNH2 575/4885 |
| US-20120214789-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX5 | ADRB2 247/4885APP 2098/4885KCNH2 428/4885 |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | P2RX2, P2RX3, TPX2 | ADRB2 464/4885APP 2723/4885KCNH2 1274/4885 |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX5 | ADRB2 247/4885APP 2098/4885KCNH2 428/4885 |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | P2RX3, P2RX2, P2RX5 | ADRB2 247/4885APP 2098/4885KCNH2 428/4885 |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX5 | ADRB2 247/4885APP 2098/4885KCNH2 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.